- Home
- LUNG
LUNG
Pulmonx Corporation
as 10-04-2024 4:00pm EST
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 248.0M | IPO Year: | 2020 |
| Target Price: | $13.71 | AVG Volume (30 days): | 237.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.46 - $14.84 | Next Earning Date: | 10-28-2024 |
| Revenue: | $76,583,000 | Revenue Growth: | 26.26% |
| Revenue Growth (this year): | 22.73% | Revenue Growth (next year): | 19.02% |
Stock Insider Trading Activity of Pulmonx Corporation (LUNG)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| French Glendon E. III | LUNG | Director | Sep 12 '24 | Sell | $8.09 | 20,000 | $161,800.00 | 1,111,974 | |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Sep 3 '24 | Sell | $6.70 | 4,586 | $30,720.74 | 299,609 | |
| Williamson Steven S. | LUNG | PRESIDENT AND CEO | Aug 20 '24 | Buy | $6.84 | 14,245 | $97,435.80 | 219,531 |
Latest Pulmonx Corporation News
LUNG Breaking Stock News: Dive into LUNG Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
GlobeNewswire
a month ago
Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference
GlobeNewswire
a month ago
Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference
Simply Wall St.
2 months ago
Analysts Are Updating Their Pulmonx Corporation (NASDAQ:LUNG) Estimates After Its Second-Quarter Results
Zacks
2 months ago
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
GlobeNewswire
2 months ago
Pulmonx Reports Second Quarter 2024 Financial Results
GlobeNewswire
2 months ago
Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
GlobeNewswire
3 months ago
Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
Compare LUNG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LUNG Pulmonx Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.